ArticleCell cycle (Georgetown, Tex.)2012

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

William H Chappell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.